Direkt zum Inhalt
Merck

Fortfahren mit

1359415

USP

Levetiracetam-Racemat

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

(RS)-α-Ethyl-2-oxo-1-pyrrolidinacetamid, 2(RS)-(2-Oxopyrrolidin-1-yl)-butyramid, Etiracetam

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis
15 mg
Warenkorb auf Verfügbarkeit prüfen
CHF 1’270.00

Über diesen Artikel

Empirische Formel (Hill-System):
C8H14N2O2
CAS-Nummer:
Molekulargewicht:
170.21
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
1529106

CHF 1’270.00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


grade

pharmaceutical primary standard

API family

levetiracetam

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCC(N1CCCC1=O)C(N)=O

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)

InChI key

HPHUVLMMVZITSG-UHFFFAOYSA-N

General description

Levetiracetam racemic mixture also know as etiracetam is an stuctural analogue ethylated piracetam drug.[1]
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levetiracetam Racemic Mixture USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Levetiracetam

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
1359404PHR2417Y0001253
Levetiracetam European Pharmacopoeia (EP) Reference Standard

Y0001253

Levetiracetam

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

grade

pharmaceutical primary standard

manufacturer/tradename

USP

manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

EDQM

format

neat

format

neat

format

-

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical

application(s)

pharmaceutical (small molecule)

API family

levetiracetam

API family

levetiracetam

API family

levetiracetam

API family

levetiracetam


pictograms

Exclamation markEnvironment

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2

Lagerklasse

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Adrian Budhram et al.
Archives of physical medicine and rehabilitation, 95(3), 588-590 (2013-09-26)
Postanoxic myoclonus is a rare manifestation after an anoxic event, with fewer than 150 cases reported in the literature. The condition is characterized by myoclonic jerks, which are worse on action than at rest, and postural lapses, ataxia, and dysarthria.
Can zinc depletion play a role in LEV-induced hair loss? Considerations from a case study.
Rocco Salvatore Calabrò et al.
Epilepsy & behavior : E&B, 29(1), 254-255 (2013-08-14)
Aaron M Cook et al.
Neurocritical care, 19(2), 210-214 (2013-08-03)
Increased creatinine clearance and subsequent elevated antimicrobial clearance is evident in many traumatic brain injury (TBI) patients due to augmented renal clearance (ARC). Little is known about the effects of ARC on other renally-eliminated medications, such as the anti-epileptic drug



Global Trade Item Number

SKUGTIN
1359415-15MG04061833851036

Questions

Reviews

No rating value

Active Filters